Advent Life Sciences
Ian joined Advent in 2012 from Chroma Therapeutics Limited, a privately held oncology-focussed R&D company, where he served as Chief Executive Officer for eight years.
Prior to joining Chroma, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK's largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently sits on the Boards of Consort Medical plc, Clinigen Group plc and is Non-Executive Chairman of Bioventix plc.
Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University.
Ian is CEO of F2G Ltd and an advisor to NeRRe Therapeutics.
This person is not in any offices
Advent Life Sciences
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe, and the USA. They are a highly experienced team with a long-standing track record of entrepreneurial and investment success through turning breakthrough science into approved medicines or medical products.